Increased Serum Hepcidin Levels in Subjects with the Metabolic Syndrome: A Population Study

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Martinelli, Nicola ^a   Traglia, Michela ^b   Campostrini, Natascia ^a   Biino, Ginevra ^b   Corbella, Michela ^a   Sala, Cinzia ^b   Busti, Fabiana ^a   Masciullo, Corrado ^b   Manna, Daniele ^a   Previtali, Sara ^c   Castagna, Annalisa ^a   Pistis, Giorgio ^b   Olivieri, Oliviero ^a   Toniolo, Daniela ^b   Camaschella, Clara ^b,c   Girelli, Domenico ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CREATININE; FERRITIN; GLUCOSE; HEMOGLOBIN; HEPCIDIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IRON; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID;

ADULT; AGE; ARTICLE; BLOOD LEVEL; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; FEMALE; FERRITIN BLOOD LEVEL; GENDER; GLUCOSE BLOOD LEVEL; HEIGHT; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; METABOLIC SYNDROME X; MUTATION; POPULATION RESEARCH; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT;

ADULT; AGED; ANALYSIS OF VARIANCE; C-REACTIVE PROTEIN; FEMALE; FERRITINS; HEPCIDINS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IRON; LINEAR MODELS; MALE; MEMBRANE PROTEINS; METABOLIC SYNDROME X; MIDDLE AGED; MUTATION; POPULATION SURVEILLANCE; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 84868095049     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048250     Document Type: Article

References (34)

1. Ford ES, Giles WH, Dietz WH, (2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287: 356-359.
2. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, et al. (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120: 1640-1645.
3. Moirand R, Mortaji AM, Loréal O, Paillard F, Brissot P, et al. (1997) A new syndrome of liver iron overload with normal transferrin saturation. Lancet 349: 95-97.
4. Riva A, Trombini P, Mariani R, Salvioni A, Coletti S, et al. (2008) Revaluation of clinical and histological criteria for diagnosis of dysmetabolic iron overload syndrome. World J Gastroenterol 14: 4745-4752.
5. Dongiovanni P, Fracanzani AL, Fargion S, Valenti L, (2011) Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. J Hepatol 55: 920-932.
6. Adams PC, Barton JC, (2011) A diagnostic approach to hyperferritinemia with a non-elevated transferrin saturation. J Hepatol 55: 453-458.
7. Ganz T, (2011) Hepcidin and iron regulation, 10 years later. Blood 117: 4425-4433.
8. Hentze MW, Muckenthaler MU, Galy B, Camaschella C, (2010) Two to tango: regulation of Mammalian iron metabolism. Cell 142: 24-38.
9. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, et al. (2004) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306: 2090-2093.
10. Wrighting DM, Andrews NC, (2006) Interleukin-6 induces hepcidin expression through STAT3. Blood 108: 3204-3209.
11. Castagna A, Campostrini N, Zaninotto F, Girelli D, (2010) Hepcidin assay in serum by SELDI-TOF-MS and other approaches. J Proteomics 73: 527-536.
12. Traglia M, Girelli D, Biino G, Campostrini N, Corbella M, et al. (2011) Association of HFE and TMPRSS6 genetic variants with iron and erythrocyte parameters is only in part dependent on serum hepcidin concentrations. J Med Genet 48: 629-634.
13. Galesloot TE, Vermeulen SH, Geurts-Moespot AJ, Klaver SM, Kroot JJ, et al. (2011) Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood 117: e218-225.
14. Bozzini C, Girelli D, Olivieri O, Martinelli N, Bassi A, et al. (2005) Prevalence of body iron excess in the metabolic syndrome. Diabetes Care 28: 2061-2063.
15. Sheu WH, Chen YT, Lee WJ, Wang CW, Lin LY, (2003) A relationship between serum ferritin and the insulin resistance syndrome is present in non-diabetic women but not in non-diabetic men. Clin Endocrinol (Oxf) 58: 380-385.
16. Jiang R, Manson JE, Meigs JB, Ma J, Rifai N, et al. (2004) Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA 291: 711-717.
17. Jehn ML, Guallar E, Clark JM, Couper D, Duncan BB, et al. (2007) A prospective study of plasma ferritin level and incident diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 165: 1047-1054.
18. Rajpathak SN, Crandall JP, Wylie-Rosett J, Kabat GC, Rohan TE, et al. (2009) The role of iron in type 2 diabetes in humans. Biochim Biophys Acta 1790: 671-681.
19. Yokomori N, Iwasa Y, Aida K, Inoue M, Tawata M, et al. (1991) Transcriptional regulation of ferritin messenger ribonucleic acid levels by insulin in cultured rat glioma cells. Endocrinology 128: 1474-1480.
20. Ackerman D, Gems D, (2012) Insulin/IGF-1 and Hypoxia Signaling Act in Concert to Regulate Iron Homeostasis in Caenorhabditis elegans. PLoS Genet 8: e1002498.
21. Cook JD, Flowers CH, Skikne BS, (2003) The quantitative assessment of body iron stores. Blood 101: 3359-3364.
22. Fernandez-Real JM, Lopez-Bermejo A, Ricart W, (2002) Cross-talk between iron metabolism and diabetes. Diabetes 51: 2348-2354.
23. Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA, et al. (2012) Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 55: 77-85.
24. Ruivard M, Lainé F, Ganz T, Olbina G, Westerman M, et al. (2009) Iron absorption in dysmetabolic iron overload syndrome is decreased and correlates with increased plasma hepcidin. J Hepatol 50: 1219-1225.
25. Trombini P, Paolini V, Pelucchi S, Mariani R, Nemeth E, et al. (2011) Hepcidin response to acute iron intake and chronic iron loading in dysmetabolic iron overload syndrome. Liver Int 31: 994-1000.
26. Aigner E, Theurl I, Theurl M, Lederer D, Haufe H, et al. (2008) Pathways underlying iron accumulation in human nonalcoholic fatty liver disease. Am J Clin Nutr 87: 1374-1383.
27. Bekri S, Gual P, Anty R, Luciani N, Dahman M, et al. (2006) Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology 131: 788-796.
28. Chung B, Matak P, McKie AT, Sharp P, (2007) Leptin increases the expression of the iron regulatory hormone hepcidin in HuH7 human hepatoma cells. Journal of Nutrition 137: 2366-2370.
29. del Giudice EM, Santoro N, Amato A, Brienza C, Calabrò P, et al. (2009) Hepcidin in obese children as a potential mediator of the association between obesity and iron deficiency. J Clin Endocrinol Metab 94: 5102-5107.
30. De Domenico I, Zhang TY, Koening CL, Branch RW, London N, et al. (2010) Hepcidin mediates transcriptional changes that modulate acute cytokine-induced inflammatory responses in mice. J Clin Invest 120: 2395-2405.
31. Ueki K, Kondo T, Tseng YH, Kahn CR, (2004) Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci U S A 101: 10422-10427.
32. Valenti L, Dongiovanni P, Motta BM, Swinkels DW, Bonara P, et al. (2011) Serum hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in patients with metabolic syndrome alterations. Arterioscler Thromb Vasc Biol 31: 683-690.
33. Saeed O, Otsuka F, Polavarapu R, Karmali V, Weiss D, et al. (2012) Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis. Arterioscler Thromb Vasc Biol 32: 299-307.
34. Li JJ, Meng X, Si HP, Zhang C, Lv HX, et al. (2012) Hepcidin Destabilizes Atherosclerotic Plaque via Overactivating Macrophages After Erythrophagocytosis. Arterioscler Thromb Vasc Biol 32: 1158-1166.